OPC, I think your go round with AU points up the true story of MannKind.

The science, the technology and the medicine are fantastic (if we can believe what the company says and what AU reports).

The management of financing, partnership and the FDA approval process have all been a complete failure.

I see management swinging for the fences, trying to hit a home run and striking out every time.

AU can be forgiven for thinking that just because the drug seems so promising that management will be successful. I have made the same mistake. I think you might feel he has too much credibility in his discussion of financial matters because he appears to have first hand knowledge of Afrezza.

Your successful trading strategy speaks for itself, and I think you should just relax about the rest, even if 300 is 3 times as much as 100 but only 200% more.